Critical Properties and Exchange Interactions of Antiferromagnetic A-spinel Lattice: A Study Through High-temperature Series Expansions

We derive high- temperature series expansions for the spin correlation functions of the A-spinel lattice. The development is extended to the order 6 in β = 1/KBT with nearest-neighbour and next-nearest neighbour interactions. The results are given for various neighbour correlation functions (up to the third). The behaviour with the temperature is presented. The critical region is studied by applying the Padé approximants method to the corresponding high- temperature series expansion of the magnetic susceptibility and the correlation length. The approach is applied to the experimental results of the particular system A-spinel CoCo2O4 . The following estimates are obtained for the familiar critical exponents:  γ =  1.382±0.010 and ν =  0.701±0.012.We derive high- temperature series expansions for the spin correlation functions of the A-spinel lattice. The development is extended to the order 6 in β = 1/KBT with nearest-neighbour and next-nearest neighbour interactions. The results are given for various neighbour correlation functions (up to the third). The behaviour with the temperature is presented. The critical region is studied by applying the Padé approximants method to the corresponding high- temperature series expansion of the magnetic susceptibility and the correlation length. The approach is applied to the experimental results of the particular system A-spinel CoCo2O4 . The following estimates are obtained for the familiar critical exponents:  γ =  1.382±0.010 and ν =  0.701±0.012

Critical Properties and Exchange Interactions of Antiferromagnetic A-spinel Lattice: A Study Through High-temperature Series Expansions.

We derive high- temperature series expansions for the spin correlation functions of the A-spinel lattice. The development is extended to the order 6 in 1 with nearest-neighbour and next-nearest neighbour interactions. The β = kBT results are given for various neighbour correlation functions (up to the third). The behaviour with the temperature is presented. The critical region is studied by applying the Padé approximants method to the corresponding high- temperature series expansion of the magnetic susceptibility and the correlation length. The approach is applied to the experimental results of the particular system A-spinel CoCo2O4. The following estimates are obtained for the familiar critical exponents: γ = 1. 382 ± 0. 010 and ν = 0. 701

PRODUCTION IN ESCHERICHIA-COLI OF ACTIVE SORGHUM PHOSPHOENOLPYRUVATE CARBOXYLASE WHICH CAN BE PHOSPHORYLATED

Phosphoenolpyruvate carboxylase (PEPC)-deficient mutants of Escherichia coli have been complemented with a plasmid bearing a full-length cDNA encoding the C4-type form of Sorghum leaf PEPC. Transformed cells grew on minimal medium. Two clones were selected which produce a functional and full-sized enzyme protein as determined by activity assays, immunochemical behavior and SDS-PAGE. In addition, regulatory phosphorylation of immunopurified recombinant PEPC was observed when the enzyme was incubated with a partially purified plant PEPC kinase. These results establish that E. coli cells produce a genuine, phosphate-free, higher-plant PEPC. Application of immunoadsorbtion chromatography to bacterial extracts makes it possible to prepare highly pure protein available for biochemical studies. RI Vidal, Jean/A-8881-2008; Lepiniec, Loic/G-5808-201

Phytochemical Compounds and Nanoparticles as Phytochemical Delivery Systems for Alzheimer’s Disease Management

Alzheimer’s disease remains one of the most widespread neurodegenerative reasons for dementia worldwide and is associated with considerable mortality and morbidity. Therefore, it has been considered a priority for research. Indeed, several risk factors are involved in the complexity of the therapeutic ways of this pathology, including age, traumatic brain injury, genetics, exposure to aluminum, infections, diabetes, vascular diseases, hypertension, dyslipidemia, and obesity. The pathophysiology of Alzheimer’s disease is mostly associated with hyperphosphorylated protein in the neuronal cytoplasm and extracellular plaques of the insoluble β-amyloid peptide. Therefore, the management of this pathology needs the screening of drugs targeting different pathological levels, such as acetylcholinesterase (AchE), amyloid β formation, and lipoxygenase inhibitors. Among the pharmacological strategies used for the management of Alzheimer’s disease, natural drugs are considered a promising therapeutic strategy. Indeed, bioactive compounds isolated from different natural sources exhibit important anti-Alzheimer effects by their effectiveness in promoting neuroplasticity and protecting against neurodegeneration as well as neuroinflammation and oxidative stress in the brain. These effects involve different sub-cellular, cellular, and/or molecular mechanisms, such as the inhibition of acetylcholinesterase (AchE), the modulation of signaling pathways, and the inhibition of oxidative stress. Moreover, some nanoparticles were recently used as phytochemical delivery systems to improve the effects of phytochemical compounds against Alzheimer’s disease. Therefore, the present work aims to provide a comprehensive overview of the key advances concerning nano-drug delivery applications of phytochemicals for Alzheimer’s disease management

Anticancer clinical efficiency and stochastic mechanisms of belinostat

Cancer progression is strongly affected by epigenetic events in addition to genetic modifications. One of the key elements in the epigenetic control of gene expression is histone modification through acetylation, which is regulated by the synergy between histone acetyltransferases (HATs) and histone deacetylases (HDACs). HDACs are thought to offer considerable potential for the development of anticancer medications, particularly when used in conjunction with other anticancer medications and/or radiotherapy. Belinostat (Beleodaq, PXD101) is a pan-HDAC unsaturated hydroxamate inhibitor with a sulfonamide group that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of refractory or relapsed peripheral T-cell lymphoma (PTCL) and solid malignancies or and other hematological tissues. This drug modifies histones and epigenetic pathways. Because HDAC and HAT imbalance can lead to downregulation of regulatory genes, resulting in tumorigenesis. Inhibition of HDACs by belinostat indirectly promotes anti-cancer therapeutic effect by provoking acetylated histone accumulation, re-establishing normal gene expressions in cancer cells and stimulating other routes such as the immune response, p27 signaling cascades, caspase 3 activation, nuclear protein poly (ADP-ribose) polymerase-1 (PARP-1) degradation, cyclin A (G2/M phase), cyclin E1 (G1/S phase) and other events. In addition, belinostat has already been discovered to increase p21WAF1 in a number of cell lines (melanoma, prostate, breast, lung, colon, and ovary). This cyclin-dependent kinase inhibitor actually has a role in processes that cause cell cycle arrest and apoptosis. Belinostat's clinical effectiveness, comprising Phase I and II studies within the areas of solid and hematological cancers, has been evidenced through several investigative trials that have supported its potential to be a valuable anti-cancer drug. The purpose of this research was to provide insight on the specific molecular processes through which belinostat inhibits HDAC. The ability to investigate new therapeutic options employing targeted therapy and acquire a deeper understanding of cancer cell abnormalities may result from a better understanding of these particular routes